How Chemotherapy-Induced Neuropathy Affects the Feet
Why the Feet Are Affected First
Chemotherapy-induced peripheral neuropathy is one of the most common lasting side effects of cancer treatment, and it is frequently underreported by patients who assume it is simply part of what they have to endure. It is not something to accept silently, because early reporting can influence treatment decisions.
Several drug classes carry the highest risk. Platinum compounds such as oxaliplatin and cisplatin, taxanes such as paclitaxel and docetaxel, vinca alkaloids such as vincristine, and agents including bortezomib and thalidomide are the most frequently implicated.
The feet are affected before the hands for the same reason they are in diabetic neuropathy. The nerves supplying the feet are the longest in the body, which means they have the greatest metabolic demand and the most vulnerable transport distance from the cell body to the nerve ending.
Damage therefore appears at the farthest point first and progresses inward, producing the characteristic stocking distribution that starts in the toes and moves up the foot and ankle. Symptoms are typically symmetric, affecting both feet in roughly equal measure.
The specific sensations vary and can coexist. Numbness, tingling, burning, electric or shooting pain, a sense of tightness as though wearing a sock that is not there, and increased sensitivity where light touch from a bedsheet becomes painful.
Symptoms Worth Reporting Immediately
Cold sensitivity is a distinctive feature of oxaliplatin, sometimes appearing within hours of infusion and producing sharp discomfort with cold surfaces or cold air. It is characteristic enough that it helps identify the responsible agent.
Dr. Chandana Halaharvi at Thrive Foot and Ankle provides protective foot care for patients across the Houston area who have lost sensation from treatment-related neuropathy, coordinating with their broader care team.
Patients throughout Sugar Land, Pearland, and the greater Houston area work with Thrive Foot and Ankle alongside their oncology team to manage the foot consequences of treatment-related neuropathy.
The most serious practical consequence is loss of protective sensation, which creates the same risk profile that diabetic patients face. A blister, a cut, a burn from hot bath water, or a pebble in the shoe can go unnoticed until it becomes a significant wound.
Daily foot inspection therefore becomes essential, using a mirror for the soles or asking someone else to look. Water temperature should be tested by hand or elbow rather than by foot, shoes should be checked before putting them on, and barefoot walking should be avoided entirely.
Protecting the Feet During and After Treatment
Balance is the other major concern. Reduced sensation degrades the feedback the body uses to stay upright, and fall risk rises measurably. Balance training, appropriate assistive devices when needed, removing tripping hazards at home, and adequate lighting all reduce that risk meaningfully.
For the pain itself, duloxetine has the strongest evidence among medications for chemotherapy-induced neuropathic pain, and gabapentin and pregabalin are commonly used. Topical agents including lidocaine and compounded preparations help some patients, and any medication choice should be coordinated with the oncology team.
Recovery varies by agent and by patient. Symptoms from some drugs improve substantially over months after treatment ends, while others leave lasting deficits, and platinum agents in particular can worsen for a period after the final dose before stabilizing. Well fitted, supportive, protective footwear remains valuable throughout.
At Thrive Foot and Ankle, we help patients with treatment-related neuropathy protect their feet and stay safely mobile. Book an appointment online for a neuropathy foot evaluation.
Comments